Chia Tai Tianqing Pharmaceutical Group Co., Ltd. clinical trial pipeline
Data updated daily from ClinicalTrials.gov, last refresh 2026-11-22
What changed in the last 30 days
3 trials changed in the last 30 days: 0 stopped, 2 with notable changes, 1 with a minor change only.
- Notable: TQA3605 Tablet in Combination With Nucleos(t)Ide Analogues(NAs) Versus NAs Alone · Chronic Hepatitis B Virus Infection Who Have Undergone Treatment and Exhibit Low Viral Load or Poor Response Start date pushed from Sep 2026 to Nov 2026
- Notable: Trials of Benmelstobart Injection Combined With Anlotinib Hydrochloride Capsules · Advanced or Unresectable Alveolar Soft Part Sarcoma Primary completion pushed from Nov 2027 to Dec 2028
- Minor: TQB2450 Injection Combined With Anlotinib Hydrochloride Capsule Versus Sunitinib · Advanced Renal Cancer Changed Registry marked status Unknown (sponsor has not verified the record since Oct 2024); last known: Active, Not Recruiting
- Stopped: terminated, suspended or withdrawn
- Notable: the plan changed
- Minor: routine updates
Active trials by phase
| Phase 1 | 15 | |
| Phase 1/2 | 11 | |
| Phase 2 | 14 | |
| Phase 3 | 19 | |
| Phase 4 | 5 |
Not charted: 1 active trial with no phase listed on ClinicalTrials.gov (typically behavioural, device, procedure and observational studies).
Disease areas by active trials, top 10 of 28
Breast Cancer (7) · Myelofibrosis (5) · Lung Cancer (4) · Head & Neck Cancer (3) · Thyroid Cancer (3) · COPD (2) · Crohn's Disease (2) · Leukemia (2) · Liver Cancer (2) · Lupus (SLE) (2)
Get alerts when Chia Tai Tianqing Pharmaceutical Group Co., Ltd.'s trials change
Status changes, date slips, and new filings: detected daily, delivered to your inbox.